OTC Obesity - USA

Date: March 22, 2010
Pages: 47
Price:
US$ 990.00
Publisher: Euromonitor International Ltd
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O00EF4DE58FEN
Leaflet:

Download PDF Leaflet

Sales of OTC obesity treatments declined by 2% in 2009. The switch of Alli, the first FDA approved weight loss drug, is proving to be a disappointment for GlaxoSmithKline, despite the state of the US population that is ripe for a scientifically tested weight loss remedy. According to the Center for Disease Control, obesity rates increased in 37 US states in 2007 over the previous year. While overall US obesity rates appear to be stabilising, 34% of US adults aged 20 or above were obese in 2006.

Euromonitor International's OTC Obesity Products in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Consumer Health industry;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
OTC Obesity in the US
Euromonitor International
March 2010

LIST OF CONTENTS AND TABLES

Executive Summary
Consumer Healthcare Industry Proves Recession-resistant
Fda Flexes Its Muscles
Private Label Proves To Be A Tenacious Competitor
Retailers Focus on Consumer Health
Product Switches Are Expected To Drive Future Growth
US Economic Slowdown Promotes Self-medication
Private Label Proves To Be A Tenacious Competitor
US Food and Drug Agency Asserts Its Weight
OTC Switches Drive Industry Growth
Blurring Lines Between Dietary Supplements, OTC Remedies, Food and Drinks
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Consumer Health Company Shares by Value 2005-2009
  Table 6 Consumer Health Brand Shares by Value 2006-2009
  Table 7 Penetration of Private Label by Sector 2004-2009
  Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Vitamins & Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
  Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
  Summary 2 Research Sources
Adams Respiratory Therapeutics Inc
Strategic Direction
Key Facts
  Summary 3 Adams Respiratory Therapeutics Inc: Key Facts
Company Background
Production
Competitive Positioning
  Summary 4 Adams Respiratory Theraputics: Competitive Position 2009
Bayer Corp
Strategic Direction
Key Facts
  Summary 5 Bayer Corp: Key Facts
Company Background
Competitive Positioning
  Summary 6 Bayer Corp: Competitive Position 2009
Chattem Inc
Strategic Direction
Key Facts
  Summary 7 Chattem Inc: Key Facts
  Summary 8 Chattem Inc: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 9 Chattem, Inc: Competitive Position 2009
General Nutrition Centers Inc
Strategic Direction
Key Facts
  Summary 10 General Nutrition Centers Inc: Key Facts
  Summary 11 General Nutrition Centers: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 12 General Nutrition Centers Inc: Competitive Position 2009
GlaxoSmithKline Consumer Health
Strategic Direction
Key Facts
  Summary 13 GlaxoSmithKline: Key Facts
Company Background
Production
Competitive Positioning
  Summary 14 GlaxoSmithKline Consumer Health: Competitive Position 2009
Johnson & Johnson Inc
Strategic Direction
Key Facts
  Summary 15 Johnson & Johnson Inc: Key Facts
Company Background
Production
Competitive Positioning
  Summary 16 Johnson & Johnson Inc: Competitive Position 2009
Melaleuca Inc
Strategic Direction
Key Facts
  Summary 17 Melaleuca Inc: Key Facts
  Summary 18 Melaleuca Inc: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 19 Melaleuca Inc: Competitive Position 2009
Nature's Sunshine Products Inc
Strategic Direction
Key Facts
  Summary 20 Nature's Sunshine Products Inc: Key Facts
  Summary 21 Nature's Sunshine Products Inc: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 22 Nature's Sunshine Products Inc: Competitive Position 2009
Procter & Gamble Co, the
Strategic Direction
Key Facts
  Summary 23 Procter & Gamble: Key Facts
Company Background
Production
Competitive Positioning
  Summary 24 Procter & Gamble Co: Competitive Position 2009
Wyeth Consumer Healthcare Inc
Strategic Direction
Key Facts
  Summary 25 Wyeth Consumer Healthcare Inc : Key Facts
Company Background
Production
Competitive Positioning
  Summary 26 Centrum Consumer Products Inc: Competitive Position 2009
Trends
Category Data
  Table 12 Sales of OTC Obesity: Value 2007-2009
  Table 13 Sales of OTC Obesity: % Value Growth 2007-2009
  Table 14 OTC Obesity Company Shares by Value 2005-2009
  Table 15 OTC Obesity Brand Shares by Value 2006-2009
  Table 16 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 17 Forecast Sales of OTC Obesity: % Value Growth 2009-2014
Skip to top


OTC Obesity - Australia US$ 990.00 Jun, 2010 · 33 pages
OTC Obesity - Austria US$ 990.00 Apr, 2010 · 31 pages
OTC Obesity - Denmark US$ 990.00 Apr, 2010 · 29 pages
OTC Obesity - Greece US$ 990.00 Mar, 2010 · 33 pages
OTC Obesity - Netherlands US$ 990.00 Jun, 2010 · 32 pages

Ask Your Question

OTC Obesity - USA
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: